APLS - Company ID 0001492422
Apellis Pharmaceuticals, Inc. trades as APLS and has a market capitalization of $5.25 B, making it the #1388 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.00B, up 28.5% from the prior year and net income of $22.39M. This page tracks Apellis Pharmaceuticals, Inc. through 1,217 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 5 fiscal years Apellis Pharmaceuticals, Inc.'s revenue grew from $250.65M to $1.00B, a compound annual growth rate of 32.0%. Net profit margin expanded from -137.6% to 2.2% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| 15-12G | - | 2026-05-26 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Delisting notice | 25-NSE | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology | Apellis Pharmaceuticals, Inc.
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors | Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Apellis Pharmaceuticals, Inc.
Please ensure Javascript is enabled for purposes of website accessibility
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference | Apellis Pharmaceuticals, Inc.
The largest companies sharing Apellis Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Apellis Pharmaceuticals, Inc. (APLS) has a market capitalization of $5.25 B as of 2026-07-09, ranking #1388 among US-listed companies.
Apellis Pharmaceuticals, Inc. reported revenue of $1.00B for fiscal year 2025, an increase of 28.5% year over year.
Yes. Apellis Pharmaceuticals, Inc. reported net income of $22.39M in its latest fiscal year.